Glucagon-like peptide-1 analog

Glucagon-like peptide-1 analogs are a new class of drug for treatment of type 2 diabetes.[1]

One of their advantages (over insulin?) is that they have a lower risk of causing hypoglycemia.

Licenced : exenatide (2005), liraglutide (2010)[2]

Under investigation : albiglutide, taspoglutide, AVE0010[1].

References

  1. ^ a b Baggio et al. (2008). "Glucagon-like Peptide-1 Analogs Other Than Exenatide". http://www.medscape.com/viewarticle/578304. 
  2. ^ "FDA Approves New Treatment for Type 2 Diabetes". http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm198638.htm. 
Insulin
Metformin# • Buformin‡ • Phenformin‡
Meglitinides/"glinides"
GLP-1 analogs
Analogs/other insulins
fast-acting (Insulin lispro • Insulin aspart • Insulin glulisine) • short-acting (Regular insulin) • long-acting (Insulin glargine • Insulin detemir • NPH insulin) • ultra-long-acting (Insulin degludec†) • inhalable Exubera‡
Other
Amylin analog
SGLT2 inhibitors
Other

M: END

anat/phys/devp/horm

noco(d)/cong/tumr, sysi/epon

proc, drug (A10/H1/H2/H3/H5)